Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Calprotectin (S100A8/A9) should preferably be measured in EDTA-plasma; results from a longitudinal study of patients with rheumatoid arthritis.

Nordal HH, Fagerhol MK, Halse AK, Hammer HB.

Scand J Clin Lab Invest. 2018 Feb - Apr;78(1-2):102-108. doi: 10.1080/00365513.2017.1419371. Epub 2017 Dec 27.

PMID:
29278951
2.

The neutrophil protein S100A12 is associated with a comprehensive ultrasonographic synovitis score in a longitudinal study of patients with rheumatoid arthritis treated with adalimumab.

Nordal HH, Brun JG, Halse AK, Jonsson R, Fagerhol MK, Hammer HB.

BMC Musculoskelet Disord. 2014 Oct 4;15:335. doi: 10.1186/1471-2474-15-335.

3.

Bacteria in the adventitia of cardiovascular disease patients with and without rheumatoid arthritis.

Curran SA, Hollan I, Erridge C, Lappin DF, Murray CA, Sturfelt G, Mikkelsen K, Førre OT, Almdahl SM, Fagerhol MK, Goodyear CS, Riggio MP.

PLoS One. 2014 May 29;9(5):e98627. doi: 10.1371/journal.pone.0098627. eCollection 2014.

4.

Calprotectin (S100A8/A9), S100A12, and EDTA-resistant S100A12 complexes (ERAC) in primary Sjögren's syndrome.

Nordal HH, Brun JG, Halse AK, Madland TM, Fagerhol MK, Jonsson R.

Scand J Rheumatol. 2014;43(1):76-8. doi: 10.3109/03009742.2013.848930. Epub 2013 Dec 3. No abstract available.

PMID:
24295066
5.

Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study.

Angel K, Provan SA, Fagerhol MK, Mowinckel P, Kvien TK, Atar D.

Am J Hypertens. 2012 Jun;25(6):644-50. doi: 10.1038/ajh.2012.12. Epub 2012 Mar 1.

6.

Large molecular size EDTA-resistant complexes containing S100A12, ERAC, in serum during inflammatory conditions.

Fagerhol MK, Larsen A, Brun JG, Hammer HB, Angel K, Kvien TK, Kinne I, Madland TM.

Scand J Clin Lab Invest. 2012 Apr;72(2):129-36. doi: 10.3109/00365513.2011.643819. Epub 2012 Jan 17.

PMID:
22248048
7.
8.

Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary.

Ødegaard E, Davidson B, Elgaaen BV, Fagerhol MK, Engh V, Onsrud M, Staff AC.

Am J Obstet Gynecol. 2008 Apr;198(4):418.e1-7. doi: 10.1016/j.ajog.2007.10.792. Epub 2008 Feb 1.

PMID:
18241816
9.

Time patterns of changes in biomarkers, symptoms and histopathology during pelvic radiotherapy.

Larsen A, Bjørge B, Klementsen B, Helgeland L, Wentzel-Larsen T, Fagerhol MK, Hovdenak N, Dahl O.

Acta Oncol. 2007;46(5):639-50.

PMID:
17562440
10.

Quantification of S100A12 (EN-RAGE) in blood varies with sampling method, calcium and heparin.

Larsen A, Bronstein IB, Dahl O, Wentzel-Larsen T, Kristoffersen EK, Fagerhol MK.

Scand J Immunol. 2007 Feb;65(2):192-201.

11.

Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis.

Hammer HB, Odegard S, Fagerhol MK, Landewé R, van der Heijde D, Uhlig T, Mowinckel P, Kvien TK.

Ann Rheum Dis. 2007 Aug;66(8):1093-7. Epub 2007 Jan 18.

12.

Calprotectin in microglia from frontal cortex is up-regulated in schizophrenia: evidence for an inflammatory process?

Foster R, Kandanearatchi A, Beasley C, Williams B, Khan N, Fagerhol MK, Everall IP.

Eur J Neurosci. 2006 Dec;24(12):3561-6.

PMID:
17229104
13.

Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease.

Lundberg JO, Hellström PM, Fagerhol MK, Weitzberg E, Roseth AG.

Nat Clin Pract Gastroenterol Hepatol. 2005 Feb;2(2):96-102. Review.

PMID:
16265127
14.

Severe anemia and neutropenia associated with hyperzincemia and hypercalprotectinemia.

Fessatou S, Fagerhol MK, Roth J, Stamoulakatou A, Kitra V, Hadarean M, Paleologos G, Chandrinou H, Sampson B, Papassotiriou I.

J Pediatr Hematol Oncol. 2005 Sep;27(9):477-80.

PMID:
16189440
15.

The effect of pre-storage cooling on 2,3-DPG levels in red cells stored in SAG-M.

Llohn AH, Vetlesen A, Fagerhol MK, Kjeldsen-Kragh J.

Transfus Apher Sci. 2005 Oct;33(2):113-8.

PMID:
16109505
16.

Increase in plasma calprotectin during long-distance running.

Fagerhol MK, Nielsen HG, Vetlesen A, Sandvik K, Lyberg T.

Scand J Clin Lab Invest. 2005;65(3):211-20.

PMID:
16095050
17.

Calprotectin, a marker of inflammation, is elevated in the maternal but not in the fetal circulation in preeclampsia.

Braekke K, Holthe MR, Harsem NK, Fagerhol MK, Staff AC.

Am J Obstet Gynecol. 2005 Jul;193(1):227-33.

PMID:
16021084
18.

The effect of intestinal colonization of germ-free pigs with Escherichia coli on calprotectin levels in plasma, intestinal and bronchoalveolar lavages.

Splíchal I, Fagerhol MK, Trebichavský I, Splíchalová A, Schulze J.

Immunobiology. 2005;209(9):681-7.

PMID:
15804046
19.

Calprotectin plasma level is elevated in preeclampsia.

Holthe MR, Staff AC, Berge LN, Fagerhol MK, Lyberg T.

Acta Obstet Gynecol Scand. 2005 Feb;84(2):151-4.

PMID:
15683375
20.

Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: a pilot study of eight stool markers.

Larsen A, Hovdenak N, Karlsdottir A, Wentzel-Larsen T, Dahl O, Fagerhol MK.

Scand J Gastroenterol. 2004 Nov;39(11):1113-8.

PMID:
15545170
21.

Induction of calprotectin release by Porphyromonas gingivalis lipopolysaccharide in human neutrophils.

Kido J, Kido R, Suryono, Kataoka M, Fagerhol MK, Nagata T.

Oral Microbiol Immunol. 2004 Jun;19(3):182-7.

PMID:
15107070
22.

Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk.

Poullis A, Foster R, Shetty A, Fagerhol MK, Mendall MA.

Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):279-84.

23.

ANCA against bactericidal/permeability-increasing protein, azurocidin, calprotectin and defensins in rheumatic and infectious diseases: prevalence and clinical associations.

Schultz H, Csernok E, Herlyn K, Reichel PH, Moosig F, Cornely OA, Fagerhol MK, Gross WL.

Clin Exp Rheumatol. 2003 Nov-Dec;21(6 Suppl 32):S117-20.

PMID:
14740437
24.

Prenatal genotyping of RHD and SRY using maternal blood.

Randen I, Hauge R, Kjeldsen-Kragh J, Fagerhol MK.

Vox Sang. 2003 Nov;85(4):300-6.

PMID:
14633256
25.
26.

Isolation and partial characterisation of a new antiproliferative substance from human leucocytes inhibiting growth of Candida albicans.

Naess-Andresen CF, Ekeberg D, Fagerhol MK, Sandvik K, Staahl L.

Mol Pathol. 2003 Aug;56(4):232-6.

27.

Emerging role of calprotectin in gastroenterology.

Poullis A, Foster R, Mendall MA, Fagerhol MK.

J Gastroenterol Hepatol. 2003 Jul;18(7):756-62. Review.

PMID:
12795745
28.

Hyperzincaemia and hypercalprotectinaemia: a new disorder of zinc metabolism.

Sampson B, Fagerhol MK, Sunderkötter C, Golden BE, Richmond P, Klein N, Kovar IZ, Beattie JH, Wolska-Kusnierz B, Saito Y, Roth J.

Lancet. 2002 Nov 30;360(9347):1742-5.

PMID:
12480428
29.

Comparison of faecal and intestinal concentrations of granulocyte marker protein and localization of gastrointestinal tumours in rats.

Kristinsson J, Nygaard K, Sundseth A, Aadland E, Fagerhol MK.

Scand J Gastroenterol. 2002 Sep;37(9):1029-33.

PMID:
12374227
30.

Faecal calprotectin: a marker of inflammation throughout the intestinal tract.

Aadland E, Fagerhol MK.

Eur J Gastroenterol Hepatol. 2002 Aug;14(8):823-5.

PMID:
12172400
31.

Age-dependent variations in fecal calprotectin concentrations in children.

Rugtveit J, Fagerhol MK.

J Pediatr Gastroenterol Nutr. 2002 Mar;34(3):323-4; author reply 324-5. No abstract available.

PMID:
11964964
32.

Expression of activation markers and cytokine mRNA by peripheral blood CD4 and CD8 T cells in atopic and nonatopic childhood asthma: effect of inhaled glucocorticoid therapy.

Gemou-Engesaeth V, Fagerhol MK, Toda M, Hamid Q, Halvorsen S, Groegaard JB, Corrigan CJ.

Pediatrics. 2002 Feb;109(2):E24.

PMID:
11826234
33.

Calprotectin inhibits matrix metalloproteinases by sequestration of zinc.

Isaksen B, Fagerhol MK.

Mol Pathol. 2001 Oct;54(5):289-92.

34.

Increased circulating levels of alpha1-antitrypsin and calprotectin are associated with reduced gas diffusion in the lungs.

Welle I, Bakke PS, Eide GE, Fagerhol MK, Omenaas E, Gulsvik A.

Eur Respir J. 2001 Jun;17(6):1105-11.

35.

Radiation-induced granulocyte transmigration predicts development of delayed structural changes in rat intestine.

Richter KK, Wang J, Fagerhol MK, Hauer-Jensen M.

Radiother Oncol. 2001 Apr;59(1):81-5.

PMID:
11295210
36.

Calprotectin, a faecal marker of organic gastrointestinal abnormality.

Fagerhol MK.

Lancet. 2000 Nov 25;356(9244):1783-4. No abstract available.

PMID:
11117904
37.

Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease.

Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I.

Gastroenterology. 2000 Jul;119(1):15-22.

PMID:
10889150
38.

Granulocyte marker protein is increased in stools from rats with azoxymethane-induced colon cancer.

Kristinsson J, Røseth AG, Sundset A, Nygaard K, Løberg EM, Paulsen JE, Aadland E, Fagerhol MK.

Scand J Gastroenterol. 1999 Dec;34(12):1216-23.

PMID:
10636069
39.

[Blood supply readiness in case of war or disasters].

Fagerhol MK, Dobloug I.

Tidsskr Nor Laegeforen. 1999 Sep 10;119(21):3159-60. Norwegian.

PMID:
10522484
40.

High prevalence of NSAID enteropathy as shown by a simple faecal test.

Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, Bjarnason I.

Gut. 1999 Sep;45(3):362-6.

42.
43.

Fecal calprotectin concentration in patients with colorectal carcinoma.

Kristinsson J, Røseth A, Fagerhol MK, Aadland E, Schjønsby H, Børmer OP, Raknerud N, Nygaard K.

Dis Colon Rectum. 1998 Mar;41(3):316-21.

PMID:
9514426
44.

Functional and clinical aspects of the myelomonocyte protein calprotectin.

Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF, Dale I.

Mol Pathol. 1997 Jun;50(3):113-23. Review. No abstract available.

45.

Association of granulocyte transmigration with structural and cellular parameters of injury in experimental radiation enteropathy.

Richter KK, Fagerhol MK, Carr JC, Winkler JM, Sung CC, Hauer-Jensen M.

Radiat Oncol Investig. 1997;5(6):275-82.

PMID:
9436244
46.

[Plasma calprotectin. A new prognostic marker of survival in alcoholic liver cirrhosis].

Homann C, Garred P, Graudal NA, Hasselqvist P, Christiansen M, Fagerhol MK, Thomsen AC.

Ugeskr Laeger. 1996 May 20;158(21):2980-4. Danish.

PMID:
8686035
47.

Nomenclature for proteins: is calprotectin a proper name for the elusive myelomonocytic protein?

Fagerhol MK.

Clin Mol Pathol. 1996 Apr;49(2):M74-9. No abstract available.

48.

Calprotectin as a marker of inflammation in cystic fibrosis.

Golden BE, Clohessy PA, Russell G, Fagerhol MK.

Arch Dis Child. 1996 Feb;74(2):136-9.

49.

Calcium binding and concomitant changes in the structure and heat stability of calprotectin (L1 protein).

Naess-Andresen CF, Egelandsdal B, Fagerhol MK.

Clin Mol Pathol. 1995 Oct;48(5):M278-84.

50.

Plasma calprotectin: a new prognostic marker of survival in alcohol-induced cirrhosis.

Homann C, Garred P, Graudal N, Hasselqvist P, Christiansen M, Fagerhol MK, Thomsen AC.

Hepatology. 1995 Apr;21(4):979-85.

PMID:
7705809

Supplemental Content

Loading ...
Support Center